ArticleWorld journal of clinical cases2025
Human papillomavirus associated serous carcinoma of the uterine cervix in a patient with long-term survival: A case report.
Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerous carcinoma of the uterine cervix (USCC) represents a rare subtype of cervical adenocarcinoma, classified into human papillomavirus (HPV)-independent and HPV-associated types. It is characterized by high invasiveness and poor prognosis, with limited global reports on this condition. CASE SUMMARY: A 58-year-old Chinese woman presented with painless vaginal bleeding after sexual intercourse, which appeared as droplets. HPV testing and histopathological analysis confirmed the diagnosis of HPV-associated primary serous carcinoma of the USCC. The patient underwent radical hysterectomy and was diagnosed with primary serous carcinoma of the uterine cervix, stage III C2 (FIGO 2018). A multimodal treatment approach, including surgery, radiotherapy, and chemotherapy, was administered. After additional concurrent chemoradiotherapy and three cycles of chemotherapy, the patient showed no evidence of disease progression and achieved long-term survival for 53 months.
conclusionUSCC is a rare and aggressive malignancy. Upon diagnosis, multimodal treatment strategies, including surgery, radiotherapy, and chemotherapy, can effectively prolong patient survival and improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.